9783540402046 - Cardiovascular Pharmacogenetics: 160 di Wilkins, Martin R. (18 risultati)

Condizione: NEW.

Condizione: New.

hardcover. Condizione: New. In shrink wrap. Looks like an interesting title!

Condizione: New. In.

Condizione: As New. Unread book in perfect condition.

Condizione: New.

Condizione: New. pp. 422 Index.

Condizione: As New. Unread book in perfect condition.

Condizione: New. pp. 422.

Condizione: New. with contributions by numerous expertsThe Human Genome Project was sold to the general public largely on the basis that a complete picture of the structure of human DNA would lead to new and better medicines. These medicines would be better because they.

Condizione: Sehr gut. Zustand: Sehr gut | Seiten: 420 | Sprache: Englisch | Produktart: Bücher | The Human Genome Project was sold to the general public largely on the basis that a complete picture of the structure of human DNA would lead to new and better medicines. These medicines would be better because they would be tailored to individual patients, maximising the chances of a therapeutic response and mi­ nimising the risks of an adverse event. Taking the idea further, pundits have pre­ dicted that the time will come when we could carry our DNA on a card which could be read rapidly and enable the physician to choose the best drug. This is the future. This is pharmacogenetics. When the draft human DNA sequence was announced and scientists were as­ ked how this would help drug development, the example most frequently given was the debrisoquine model - where poor metabolisers of this hypotensive agent are exposed to higher plasma levels from a standard dose and at risk of collapse from excessive hypotension. This observation was made over 20 years ago and predated designs to sequence the human genome. Nonetheless, it raised aware­ ness of variation in drug metabolism and was correctly assigned to genetic poly­ morphisms affecting CYP2D6. Together with the discovery of pseudocholinestera­ se deficiency, it marked the birth of pharmacogenetics. The debrisoquine example is an interesting one and worthy of further analysis.

Hardback. Condizione: New. 2004 ed. This volume intends to provide a panorama of our current understanding of the role of genetic information in the management of cardiovascular disease. A recurring plea from the contributors is the need for more hypothesis-driven, rigorously conducted and analysed clinical research. Perhaps this compilation of knowledge will provide a springboard for the design of informative clinical studies.

Buch. Condizione: Neu. Druck auf Anfrage Neuware - Printed after ordering - The Human Genome Project was sold to the general public largely on the basis that a complete picture of the structure of human DNA would lead to new and better medicines. These medicines would be better because they would be tailored to individual patients, maximising the chances of a therapeutic response and mi nimising the risks of an adverse event. Taking the idea further, pundits have pre dicted that the time will come when we could carry our DNA on a card which could be read rapidly and enable the physician to choose the best drug. This is the future. This is pharmacogenetics. When the draft human DNA sequence was announced and scientists were as ked how this would help drug development, the example most frequently given was the debrisoquine model - where poor metabolisers of this hypotensive agent are exposed to higher plasma levels from a standard dose and at risk of collapse from excessive hypotension. This observation was made over 20 years ago and predated designs to sequence the human genome. Nonetheless, it raised aware ness of variation in drug metabolism and was correctly assigned to genetic poly morphisms affecting CYP2D6. Together with the discovery of pseudocholinestera se deficiency, it marked the birth of pharmacogenetics. The debrisoquine example is an interesting one and worthy of further analysis.

Hardcover. Condizione: Brand New. 1st edition. 407 pages. 9.25x6.25x1.00 inches. In Stock.

Hardcover. Condizione: Brand New. 1st edition. 407 pages. 9.25x6.25x1.00 inches. In Stock. This item is printed on demand.

Buch. Condizione: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -The Human Genome Project was sold to the general public largely on the basis that a complete picture of the structure of human DNA would lead to new and better medicines. These medicines would be better because they would be tailored to individual patients, maximising the chances of a therapeutic response and mi nimising the risks of an adverse event. Taking the idea further, pundits have pre dicted that the time will come when we could carry our DNA on a card which could be read rapidly and enable the physician to choose the best drug. This is the future. This is pharmacogenetics. When the draft human DNA sequence was announced and scientists were as ked how this would help drug development, the example most frequently given was the debrisoquine model - where poor metabolisers of this hypotensive agent are exposed to higher plasma levels from a standard dose and at risk of collapse from excessive hypotension. This observation was made over 20 years ago and predated designs to sequence the human genome. Nonetheless, it raised aware ness of variation in drug metabolism and was correctly assigned to genetic poly morphisms affecting CYP2D6. Together with the discovery of pseudocholinestera se deficiency, it marked the birth of pharmacogenetics. The debrisoquine example is an interesting one and worthy of further analysis. 420 pp. Englisch.

Buch. Condizione: Neu. Cardiovascular Pharmacogenetics | Martin R. Wilkins | Buch | Handbook of Experimental Pharmacology | x | Englisch | 2003 | Springer | EAN 9783540402046 | Verantwortliche Person für die EU: Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg, juergen[dot]hartmann[at]springer[dot]com | Anbieter: preigu Print on Demand.

Buch. Condizione: Neu. This item is printed on demand - Print on Demand Titel. Neuware -The Human Genome Project was sold to the general public largely on the basis that a complete picture of the structure of human DNA would lead to new and better medicines. These medicines would be better because they would be tailored to individual patients, maximising the chances of a therapeutic response and mi nimising the risks of an adverse event. Taking the idea further, pundits have pre dicted that the time will come when we could carry our DNA on a card which could be read rapidly and enable the physician to choose the best drug. This is the future. This is pharmacogenetics. When the draft human DNA sequence was announced and scientists were as ked how this would help drug development, the example most frequently given was the debrisoquine model - where poor metabolisers of this hypotensive agent are exposed to higher plasma levels from a standard dose and at risk of collapse from excessive hypotension. This observation was made over 20 years ago and predated designs to sequence the human genome. Nonetheless, it raised aware ness of variation in drug metabolism and was correctly assigned to genetic poly morphisms affecting CYP2D6. Together with the discovery of pseudocholinestera se deficiency, it marked the birth of pharmacogenetics. The debrisoquine example is an interesting one and worthy of further analysis.Springer-Verlag KG, Sachsenplatz 4-6, 1201 Wien 420 pp. Englisch.